leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals set to file regulatory approval for Evolve dry eye products in Canada after UK-based partner clears final submission hurdle

The firm said its UK partner Medicom Healthcare received the final certificate necessary to complete the regulatory submission for Health Canada approval

Aequus Pharmaceuticals Inc. -
The Evolve line includes a preservative-free prescription product for the treatment of open-angle glaucoma and a range of supporting diagnostics

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) is getting ready to file for regulatory approval in Canada for the Evolve line of dry eye products, it said Monday.

The news comes as the Vancouver-based firm said its UK partner Medicom Healthcare received the final certificate for the Canadian Medical Device Single Audit Program necessary to complete the regulatory submission for Health Canada approval.

Aequus said it expects to file for Canadian regulatory approval for the first three dry eye products in the Evolve line within the next 10 days.

READ: Aequus Pharmaceuticals posts second-highest quarterly revenue as demand grows for opthalmic and transplant products

The dry eye drops will be filed as New Class II medical devices with Health Canada, which usually comes with an expected review period of up to 30 days, Acasti said in a statement.

“Over the past months, the marketing team has worked diligently to prepare for the launch of Evolve in Canada,” said Doug Janzen, CEO of Aequus.

Janzen said it was a “long and frustrating” wait for both the pharmaceutical company and Medicom, but the firm managed to utilize the time well and are ready to get to work.

“We are excited to have received this final piece required for the regulatory submission with Health Canada and look forward to providing dry eye patients in Canada with this exceptional line of products in the near future,” Janzen added.

Launched in 2015 in Europe, the Evolve brand has grown to five products across 35 countries. Its line includes a preservative-free prescription product for the treatment of open-angle glaucoma and a range of supporting diagnostics.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.115 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

3 days, 7 hours ago

2 min read